Recent developments in pradimicin-benanomicin and triazole antibiotics

Bibliography

• ODDS FC, SCHMID J, SOLL DR: Epidemiology of Can infections in AIDS. In: Mycoses in AIDS Patients. Vanden Bossche H, MacKenzie DVVR, Cauwenberg G, Cutsem JV, Drouhet E, Dupont B (Eds.), Plenum Press, London (1990) pp67–74.
   Google Scholar
• CASADEVALL A, SPITZER ED, WEBB D, RINALDI MG: Susceptibilities of serial Cryptococcus neoformans iso-lates from patients with recurrent cryptococcal menin-gitis to amphotericin B and fluconazole. Antimicrob. Agents Chemother. (1993) 37:1383–1386.
   PubMed Web of Science ®Google Scholar
• EDMAN JC, KOVACS JA, MASUR H et al: Ribosomal RNA sequence shows Pneumocystis carinii to be a member of the fungi. Nature (1988) 334:519–522.
   PubMed Web of Science ®Google Scholar
• OKI T, KONISHI M, TOMATSU K et al: Pradimicin, a novel class of potent antifungal antibiotics. J. Antibiot (1988) 41:1701–1704.
   PubMed Web of Science ®Google Scholar
• TOMITA K, NISHIO M, SAITOH K et al: Pradimicin A, B and C: new antifungal antibiotics. L Taxonomy, produc-tion, isolation and physico-chemical properties. J. An-tibiot. (1990) 43:755–762.
   Google Scholar
• TAKEUCHI T, HARA T, NAGANAWA H etal.: New antifun-gal antibiotics, benanomicins A and B from an Acti-nomycete. Antibiot. (1988) 41:807–811.
   Google Scholar
• OKI T, OSAMU T, HIRANO M eta].: Pradimicins A, B and C: new antifungal antibiotics. II. In vitro and in vivo biological activities. J. Antibiot (1990) 43:763–770.
   PubMed Web of Science ®Google Scholar
• SAWADA Y, HISHIO M, YAMAMATO H et al: New antifun-gal antibiotics, pradimicin D and E. Glycine analogs of pradimicins A and C. J. Antibiot (1990) 43:771–777.
   PubMed Web of Science ®Google Scholar
• SAWADA Y, HATORI M, YAMAMOTO H et al: New anti-fimgal antibiotics pradimicins FA-1 and FA-2: D-serine analogs of pradimicins A and C. J. Antibiot (1990) 43:1223–1229.
   PubMed Web of Science ®Google Scholar
• SAITOH K, SUZUKI K, HIRANO M et al: Pradimicins FSand FB, new pradimicin analogs: directed production, structures and biological activities. J. Antibiot (1993) 46:398–405.
   PubMed Web of Science ®Google Scholar
• SAITOH K, SAWADA Y, TOMITA K, et al: Pradimicins Land FL: new pradimicin congeners from Actin omadura verrucosospora subsp. neohibisca. J. Antibiot (1993) 46:387–397.
   PubMed Web of Science ®Google Scholar
• SAITOH K, TSUNO T, KAKUSHIMA M eta].: Pradimicin S,a new pradimicin analog. IL Isolation and structure elucidation. J. Antibiot (1993) 46:406–411.
   Google Scholar
• KONDO S, GOMI S, UOTANI K et al.: Isolation of newminor benanomicins. j Antibiot. (1991) 44:123–129.
   PubMed Web of Science ®Google Scholar
• FUKAGAWA Y, UEKI T, NUMATA K-I, OKI T: Pradimicins and benanomicins, sugar-recognizing antibiotics: theirnovel mode of antifungal action and conceptual signifi-cance. Actinomycetology (1991) 7:1–22.
   Google Scholar
• An excellent review of pradimicins and benanomicins.
   Google Scholar
• WATANABE M, GOMI S, TOHYAMA H eta].: Binding of benanomicin A to fungal cells in reference to its fungi-cidal action. J. Antibiot. (1996) 49:366–373.
   Google Scholar
• OKI T: Pradimicin, a novel antifungal agent. In: New Approaches for Anfffungal Drugs. Fernandes PB (Ed.), Birk-hauser, Boston (1992).
   Google Scholar
• ABURAKI S, OKUYAMA S, HOSHI H et al: Synthesis and antifungal activity of pradimicin derivatives. Modifica-tions on the aglycone part. J. Antibiot. (1993) 46:1447–1457.
   PubMed Web of Science ®Google Scholar
• CID VJ, DURAN A, DEL REY F eta].: Molecular basis of cellintegrity and morphogenesis in Saccharomyces cere-visiae. Microbiol. Rev. (1995) 59:345–386.
   Google Scholar
• UEKI T, NUMATA K-I, SAWADA Y et al.: Studies on the mode of antifungal action of pradimicin antibiotics. L Lectin-mimic binding of BMY-28864 to yeast mannan in the presence of calcium. J. Antibiot. (1993) 46:149–161.
   Google Scholar
• UEKI T, NUMATA K-I, SAWADA Y et al.: Studies on the mode of antifungal action of pradimicin antibiotics. II. D-Mannopyranoside-binding site and calcium-binding site .j Antibiot. (1993) 46:455–464.
   Google Scholar
• UEKI T, OKA M, FUKAGAWA Y, OKI T: Studies on themode of antifungal action of pradimicin antibiotics. III. Spectrophotometric sequence analysis of the ternary complex formation of BMY-28864 with D-mannopyra-noside and calcium. J. Antibiot (1993) 46:465–477.
   Google Scholar
• SAWADA Y, MURAKAMI T, UEKI T et al.: Mannan-medi-ated anticandidal activity of BMY-28864, a new water-soluble pradimicin derivative. J. Antibiot. (1991) 44:119–121.
   PubMed Web of Science ®Google Scholar
• NUMATA K, UEKI T, NAITO N et al: Morphologicalchanges of Candida albicans induced by BMY-28864, a highly water-soluble pradimicin derivative. j Electron Microscop. (1993) 42:147–155.
   PubMed Web of Science ®Google Scholar
• KAKUSHIMA M, MASUYOSHI S, HIRANO M eta].: In vitroand in vivo antifungal activities of BMY-28864, a water-soluble pradimicin derivative. Antimicrob. Agents Chemother. (1991) 35:2185–2190.
   Google Scholar
• OKI T, KAKUSHIMA M, HIRANO M et al.: In vitro and in vivo antifungal activities of BMS-181184. j Antibiot. (1992) 45:1512–1517.
   PubMed Web of Science ®Google Scholar
• FUNG-TOMC J, MINASSIAN B, HUCZKO E et al: In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184. Antimicrob. Agents Chemother. (1995) 39:295–300.
   Google Scholar
• A comprehensive comparison of BMS-181184, amphotericin B and fluconazole.
   Google Scholar
• WARDLE HM, LAW D, DENNING DW: In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various Candida spp. Antimi-crob. Agents Chemother. (1996) 40:2229–2231.
   PubMed Web of Science ®Google Scholar
• HOBAN D, KABANI A, KARLOWSKY J et al: In vitro antifungal activity of BMS181184 against systemic iso-lates of Candida, Cryptococcus and Blastomyces spp. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996):F179.
   Google Scholar
• OAKLEY KL, MOORE CB, DENNING DW: Activity of pradimicin BMS-181184 against Aspergillus spp. 36th Interscience Conference on Antimicrobial Agents and Che-motherapy New Orleans, USA (1996):180.
   Google Scholar
• BARTNICKI-GARCIA S: Cell wall chemistry, morpho-genesis, and taxoromy of fungi. Ann. Rev. Microbic)]. (1968) 22:87–108.
   PubMed Web of Science ®Google Scholar
• CROOK EM, JOHNSTON IR: The qualitative analysis of the cell walls of selected species of fungi. Biochem. (1962) 33:325–331.
   Google Scholar
• RUIZ-HERRERA J: Fungal Cell Wall: structure, synthesis, and assembly CRC Press, Boca Raton (1992).
   Google Scholar
• MIKAMI Y, SCALARONE GM, KURITA N etat: Comparative studies on the postantifungal effect of cispentacin and pradimicin (BMY-28864) on Candida albicans. fpn. Med. Mycol. (1992) 33:355–360.
   Google Scholar
• CLARK JM, FERRARO C, STOLFI T et al.: Efficacy of BMS-181184 in experimental fungal infections in mice. 33rd Interscience Conference on Antimicrobial Agents and Che-motherapy New Orleans, USA (1993):389.
   Google Scholar
• RESTREPO M, NAJVAR L, BOCANEGRA R et at: Compari-son of the efficacy of BMS-181184 and amphotericin B against hematogenous Candida tropicalis infection in immunosuppressed mice. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (1996):F183.
   Google Scholar
• GONZALEZ CE, SHETTY D, GIRT N et al.: Efficacy of pradimicin against disseminated candidias is. 36th Inter-science Conference on Antimicrobial Agents and Chemother-apy. New Orleans, USA (1996):F181.
   Google Scholar
• GONZALEZ CE, SHETTY D, GIRT N et al.: Efficacy of pradimicin against invasive pulmonary aspergillosis. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996):F182.
   Google Scholar
• YASUOKA A, OKA S, KOMURO K et at: Successful treat-ment of Pneumocystis carinii pneumonia in mice with benanomicin A (ME1451). Antimicrob. Agents Chemother. (1995) 39:720–724.
   PubMed Web of Science ®Google Scholar
• YANG H, DRAIN RL, CLARK JM: Evaluation of the pradimi-cM analogue BMS-181184 against Pneumocystis carinii in an experimentally inoculated mice model. 34th Inter-science Conference on Antimicrobial Agents and Chemother-apy Orlando, USA (1994), F713.
   Google Scholar
• TANABE K, TAKASAKI S, WATANABE J et al.: Glycoprote-ins composed of major surface immunodeterminants of Pneumocystis carinii. Infect. Immun. (1989) 57:1363–1368.
   PubMed Web of Science ®Google Scholar
• TANABE A, NAKASHIMA H, YOSHIDA 0 et al.: Inhibitory effect of new antibiotic, pradimicin A on infectivity, cytopathic effect and replication of human immunode-ficiency virus in vitro. J. A ntibiot (1988) 41:1708–1710.
   Google Scholar
• TANABE-TOCHIKURA A, TOCHIKURA TS, YOSHIDA 0 et al.: Pradimicin A inhibition of human immunodefi-ciency virus: attenuation by mannan. Virology (1990) 176:467–473.
   Google Scholar
• KURACHI T, MORITA I, OKI T et al.: Expression on outer membranes of mannose residues, which are involved in osteoclast formation via cellular fusion events.J. Chem. (1994) 269:17572–17576.
   Google Scholar
• TAYLOR ME, DRICKAMER K: Structural requirements for high affinity binding of complex ligands by the macro- phage mannose receptor. J. Biol. Chem. (1993) 268:399–404.
   PubMed Web of Science ®Google Scholar
• WARNER GL, JOHANSON LC, KOWOLENKO MD et al.:Mechanism of immunotoxicicity associated with haemolysis caused by anti-fungal, pradimicin deriva-tives, in the Cynomolgus monkey. J. Immunol. (1993) 150:A225, 1287.
   Google Scholar
• GOA KL, BARRADELL LB: Fluconazole. An update of itspharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. Drugs (1995) 50:658–690.
   Google Scholar
• BALLY G, PERRY FM, DENNING DW, MANDAL BK: Flu-conazole-resistant candidosis in an HIV cohort. AIDS (1994) 8:787–792.
   PubMed Web of Science ®Google Scholar
• SPITZER ED, SPITZER SG, FREUNDLICH LF, CASADEVALLA: Persistence of initial infection in recurrent Crypto-coccus neoformans meningitis. Lancet (1993) 341:595–596.
   PubMed Web of Science ®Google Scholar
• ZUGER A, LOUIE E, HOLZMAN RS et al.: Cryptococcaldisease inpatients with the acquired immunodeficency syndrome. Ann. Intern. Med (1986) 104:234–240.
   PubMed Web of Science ®Google Scholar
• HARIA M, BRYSON HM, GOA KL: Itraconazole. A reap-praisal of its pharmacological properties and t her apeu-tic use in the management of superficial fungal infections. Drugs (1996) 51:585–620
   Google Scholar
• POIRIER JM, BERLIOZ F, ISNARD F, CHEYMOL G: Markedintra- and inter-patient variability of itraconazole steady state plasma concentrations. Therapie (1996) 51:163–167.
   PubMed Web of Science ®Google Scholar
• BARBARO G, BARBARINI G, DI LORENZO G: Fluconazolecompared with itraconazole in the treatment of esopha-geal candidiasis in AIDS patients: a double-blind, ran-domized, controlled clinical study. Scand. J. Infect Di. (1995) 27:613–617.
   PubMed Web of Science ®Google Scholar
• JOHNSON EM, DAVEY KG, SZEKELY A, WARNOCK DW:
   Google Scholar
• •Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species. J. Antimi-crob. Chemother. (1995) 36:787–793.
   Google Scholar
• A comprehensive comparison between itraconazole and fluconazole susceptibilities to Candida spp.
   Google Scholar
• CHRYSSANTHOU E, TORSSANDER J, PETRINI B: Oral Can-dida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients. Scand. J. Infect. Dis. (1995) 27:391–395.
   PubMed Web of Science ®Google Scholar
• DENNING DW, TUCKER RM, HANSON LH, STEVENS DA: Treatment of invasive aspergillosis with itraconazole. Am. J. Med. (1989) 86:791–800.
   PubMed Web of Science ®Google Scholar
• VIVIANI MA, TORTORANO AM, LANGER M et al.: Experi-ence with itraconazole in cryptococcosis and aspergil-losis. J. Infection (1989) 18:151–165.
   PubMed Web of Science ®Google Scholar
• VENKATESWARLU K, DENNING DW, MANNING NJ, KELLYSL:. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob. Agents Chemother. (1996) 40:2443–2446.
   Google Scholar
• VANDEN BOSSCHE H, MARICHAL P, GORRENS J et al.:Mutation in cytochrome P450-dependent 14a-demethy-lase results in decreased affinity for azole antifungals. Biochem. Soc. Trans. (1990) 18:56–59.
   PubMed Web of Science ®Google Scholar
• VANDEN BOSSCHE H, MARICHAL P, ODDS FC et al.: Characterization of an azole-resistant Candidaglabrata isolate. Antimicrob.Agents Chemother. (1992) 36:2602–2610.
   PubMed Web of Science ®Google Scholar
• LAMB DC, CORRAN A, BALDWIN BC et aL: Resistant P45051A1 activity in azole antifungal tolerant Crypto-coccus neoformans from AIDS patients. FEBSLett. (1995) 368:326–330.
   PubMed Web of Science ®Google Scholar
• SANGLARD D, KUCHLER K, ISCHER F et al.: Mechanisms of resistance to azole antifungal agents in Can didaalbicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother. (1995) 39:2378–2386.
   Google Scholar
• Detailed study of efflux pumps associated with azole resistance.
   Google Scholar
• WATSON PF, ROSE ME, ELLIS SW et al: Defective sterol C5-6 desaturation and azole resistance: a new hypothe-sis for the mode of action of azole antifungals. Biochem. Biophys. Res. Commun. (1989) 164:1170–1175.
   PubMed Web of Science ®Google Scholar
• KELLEY SL, ARNOLDI A, KELLY DE: Molecular genetic analysis of azole antifungal mode of action. Biochem.Soc. Trans. (1993) 21:1034-1038. An excellent review of cytochrome P450.
   Google Scholar
• GERBER A, HITCHOCK CA, SWARTZ JE et al.: Deletion of the Canglabrata ERG3 and ERG11 genes: effect oncell viability, cell growth, sterol composition, and anti-fungal susceptibility. Antimicrob. Agents Chemother. (1995) 39:2708–2717.
   PubMed Web of Science ®Google Scholar
• VENKATESWARLU K, DENNING DW, MANNING NJ, KELLY SL: Resistance to fluconazole in Candida albicans from AIDS patients correlated with reduced intracellular ac-cumulation of drug. FEZ Microbiol. Lett. (1995) 131:337–341.
   PubMed Web of Science ®Google Scholar
• PARKINSON T, FALCONER DJ, HITCHCOCK CA: Flucona-zole resistance due to energy-dependent drug efflux in Candida glabrata. Antimicrob. Agents Chemother. (1995) 39:1696–1699.
   PubMed Web of Science ®Google Scholar
• JOSEPH-HORNET, HOLLOMON D, THOMAS LOEFFLER RS, KELLY SI: Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob. Agents Chemother. (1995) 39:1526–1529.
   PubMed Web of Science ®Google Scholar
• FLING ME, KOPF J, TAMARKIN A et aL: Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate. Mol. Gen. Genet (1991) 227:318–329.
   PubMedGoogle Scholar
• PRASAD R, DEWERGIFOSSE P, GOFFEAU A, BALZI E: Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resis-tance to drugs and antiftmgals. Curr. Genet (1995) 27:320–329.
   PubMed Web of Science ®Google Scholar
• SANGLARD D: Efflux-mediated resistance to azole anti-fungal agents in yeasts. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA. (1996):S39.
   Google Scholar
• NATIONAL COMMITTEE ON CLINICAL LABORATORY
   Google Scholar
• ••STANDARDS: Reference method for broth dilution antifungalsusceptibility testing of yeasts; approved standard. M27-A National Committee on Clinical Laboratory Standards (In press).
   Google Scholar
• Standardisation of the susceptibility test method for antifungal agents.
   Google Scholar
• GIRIJAVALLABHAN VM, SAKSENA AK, LOVEY RG eta': Sch 56592, a novel orally active broad spectrum antifungal agent. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA (1995):F61.
   Google Scholar
• PFALLER MA, ZERVA L, MESSER S, JONES R: Antiftmgal activity of a new triazole, SCH 56592, compared with four other antifungal agents tested against clinical iso-lates of Candida spp. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (1996):F87.
   Google Scholar
• LAW D, DENNING DW: In vitro activity of Schering 56592, compared with fluconazole and itraconazole against Candida spp. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (1996):F88.
   Google Scholar
• MUNAYYER H, SHAW KJ, HARE RS et aL: SCH 56592 is a potent inhibitor of sterol C14 demethylation in fungi. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996):F92.
   Google Scholar
• PARMEGIANI R, CACCIAPUOTI A, LOEBENBERG D et aL: In vitro activity of SCH 56592, a new antifungal agent. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995):62.
   Google Scholar
• PERFECT JR, SCHELL WA: In vitro efficacy of the azole, SCH 56592, compared to amphotericin B, fluconazole, and itraconazole versus Cryptococcus neoformans. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995):F64.
   Google Scholar
• FOTHERGILL AW, SUTTON DA, RINALDI MG: An in vitro head-to-head comparison of Schering 56592, am-photericin B, fluconazole, and itraconazole against a spectrum of filamentous fungi. 36th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy. New Or-leans, USA (1996):F89.
   Google Scholar
• OAKLEY KL, MOORE CB, DENNING, DW: In vitro activity of SCH-56592 against Aspergillus spp. and comparison with itraconazole and amphotericin B. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996):F90.
   Google Scholar
• DUPONT B, IMPROVISI L, DROMER F: In vitro and in vivo activity of a new antifungal agent SC1156592. 36th Inter-science Conference on Antimicrobial Agents and Chemother-apy. New Orleans, USA (1996):F93.
   Google Scholar
• SUGAR AM, LIU X-P: In vitroactivity of SCH 56592 against Blastomyces dermatitidis. 35th Interscience Conf. on An-timicrobial Agents and Chemotherapy San Francisco, USA (1995): F65.
   Google Scholar
• WHEAT J, BICK C, CONNOLLY P et al.: Comparison of a new triazole, Schering 56592, with itraconazole and amphotericin B for treatment of murine histoplas-mosis. 36th Interscience Conference on Antimicrobial Agpnts and Chemotherapy New Orleans, USA (1995):F101.
   Google Scholar
• LUTZ JE, CLEMONS KV, STEVENS DA: Efficacy of SCH 56592 in a murine model of systemic coccidioidomy-cosis. 36th Interscience Conference on Antimicrobial Aunts and Chemotherapy New Orleans, USA (1996):F100.
   Google Scholar
• YAROSH-TOMAINE T, MUNAYYER H, SHAW KJ et aL: Studies on fungal resistance to SCH 56592. 36th Inter-science Conference on Antimicrobi a I Agents and Chemother-apy. New Orleans, USA (1996):F91.
   Google Scholar
• NOMEIR A, KUMARI P, HILBERT MJ et aL: Comparative pharmacokinetics of a new triazole antifungal agent SCH 56592. 35th Interscience Conference on Antimicrobia Agents and Chemotherapy San Francisco, USA (1995:F68.
   Google Scholar
• NOMEIR AA, KUMARI P, LOEBENBERG D et aL: Bioavail-ability of SCH 56592, a new broad spectrum triazole antifungal agent, from various formulations. 36th Inter-science Conference on Antimicrobial Agents and Chemother-apy. New Orleans, USA (1996):F103.
   Google Scholar
• CACCIAPUOTI A, PARMEGIANI R, LOEBENBERG D et al.: Efficacy of SCH 56592 in pulmonary aspergillosis and candidiasis in mice. 35th Interscience Conference on An-timicrobial Agents and Chemotherapy. San Francisco, USA (1995):F66.
   Google Scholar
• MILLER GH, LOEBENBERG D, ANTONACCI B et al.: In vitro-in vivo correlations for the azole antifungals SC1156592, SC1139304, SC1151048, fluconazole & itra-conazole in candidiasis and aspergillosis. 36th Inter-science Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (1996):F94.
   Google Scholar
• COLE GT, SESHAN KR, LOEBENBERG D: Evaluation of SCH 56592 in clearance of GI mucosalcandidias is from mice with retroviral-induced immunodeficiency. 36th Inter-science Conference on Antimicrobial Agents and Chemother-apy. New Orleans, USA (1996):F95.
   Google Scholar
• PARMEGIANI R, CACCIAPUOTI A, LOEBENBERG D et al.: Efficacy of SCH 56592 in topical infection models. 35th Interscience Conference on Antimicrobial Agents and Che-motherapy San Francisco, USA (1995):F67.
   Google Scholar
• CACCIAPUOTI A, LOEBENBERG D, FRANK D et al.: Effect of delayed and extended treatment with SCH 56592 or concomitant treatment with amphotericin B in murine models of pulmonary aspergillosis and systemic can-didiasis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA (1995):F66.
   Google Scholar
• OAKLEY KL, MORRISSEY G, DENNING DW: Efficacy of Sch-56592 in 2 immunocompromised murine models of invasive aspergillosis. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (1996):F97.
   Google Scholar
• PATTERSON TF, KIRKPATRICK VVR, MCATEE RK, LOEBEN-BERG D: Efficacy of SCH 56592 in a rabbit model of invasive aspergillosis. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (1996):F98.
   Google Scholar
• GRAYBILL J, NAJVAR L, BOCANEGRA R et al: Treatment of murine pulmonary aspergillosis with Sch 56592. 36th Interscience Conference on Antimicrobial Agents and Che-motherapy New Orleans, USA (1996):F99.
   Google Scholar
• LUTZ JE, CLEMONS KV, STEVENS DA: Efficacy of SCH 56592 in a murine model of systemic coccidiodomy-cosis. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (1996). Abstract F100.
   Google Scholar
• URBINA JA, PAYARES G, SANOJA C et al: In vitro and in vivo antiproliferative effects of SCH 56592 against Try-panosoma cruzi the causative agent of Chagas disease. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (1996). Abstract F101.
   Google Scholar
• RICHARDSON K, BELL AS, DICKINSON RP et al.: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: synthesis and SAR. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995):F69.
   Google Scholar
• TROKE PF, BELL AS, DICKINSON RP et al: UK-109,496, a novel, wide-spectrum triazole derivative for the treat-ment of systemic fungal infections: discovery andanti-fungal properties. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA (1995):F70.
   Google Scholar
• HITCHCOCK CA, PYE GW, OLIVER GP, TROKE PF: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro. 35th Interscience Conference on Antimicrobi a I AgentsandChemotherapy. San Francisco, USA (1995):F72.
   Google Scholar
• SANATI H, BELANGER PH, FRATTI RA, GHANNOUM MA: Effect of voriconazole (UK-109,496) on the sterol bio-synthesis of Candida al bicans and Candida krusei. 36th Interscience Conference on Antimicrobial Agents and Che-motherapy New Orleans, USA (1996):C65.
   Google Scholar
• BARCHIESI F, RESTREPO M, MCGOUGH DA, RINALDI MG: In vitro activity of a new antifungal triazole: UK-109,496. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy.San Francisco, USA (1995):F71.
   Google Scholar
• OAKLEY KL, MOORE CB, DENNING DW: In vitro activity of voriconazole against Aspergillus spp. and compari-son with amphotericin B and itraconazole. 36th Inter-science Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996). Abstract F81.
   Google Scholar
• ESPINEL-INGROFF A, FLYNN T: Antifungal activity of the new triazole voriconazole against established, new and emerging yeast pathogens: a comparative study. 36th Interscience Conference on Antimicrobial Agents and Che-motherapy. New Orleans, USA (1996):F83.
   Google Scholar
• ESPINEL-INGROFF A: Evaluation of the in vitro activity of the new triazole voriconazole against opportunistic filamentous fungi. 36th Interscience Conference on Antimi-crobial Agents and Chemotherapy New Orleans, USA (1996):F84.
   Google Scholar
• SUTTON DA, FOTHERGILL AW, BARCHIESI FJ, RINALDI MG: In vitro activity of voriconazole against dimorphic fungi. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, USA (1996):F85.
   Google Scholar
• MCGINNIS MR, PASARELL L, COOPER CR JR: In vitro susceptibility of clinical mould isolates to UK-109,496, amphotericin B, fluconazole, and itraconazole. 35th Interscience Conference on Antimicrobial Agents and Che-motherapy. San Francisco, USA (1995):E76.
   Google Scholar
• JEZEQUEL SG, CLARK M, COLE S et al.: UK-109,496, a novel, wide-spectrum triazole derivative for the treat-ment of fungal infections: pre-clinical pharmacokinet-ics. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995):F76.
   Google Scholar
• JEZEQUEL SG, CLARK M, EVANS K et al: UK-109,496, a novel, wide-spectrum triazole derivative for the treat-ment of fungal infections: disposition in animals. 35th Interscience Conference on Antimicrobial Agents and Che-motherapy. San Francisco, USA (1995):F77.
   Google Scholar
• TROKE PF, BRAMMER KW, HITCHCOCK CA et al.: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic models and early clinical efficacy in oropharyngeal candidiasis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA (1995):F73.
   Google Scholar
• HITCHCOCK CA, ANDREW RJ, lEWIS BGH, TROKE PF: UK-109, 496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activ-ity in experimental infection with Cryptococcus. 35th Interscience Conference on Antimicrobial Agents and Che-motherapy. San Francisco, USA (1995):F75.
   Google Scholar
• HITCHCOCK CA, ANDREW RJ, 1EWIS BGH, TROKE PF: UK-109, 496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activ-ity in experimental infectons with Aspergillus. 35th Interscience Conference on Antimicrobial Agents and Che-motherapy San Francisco, USA (1995):F74.
   Google Scholar
• MARTIN MV, YEATS J, HITCHCOCK CA: Voriconazole (UK-109,496): a novel, wide-spectrum triazole deriva-tive for the treatment of fungal infections: antifungal activity in experimental Asp ergillus endocarditis. 36th Interscience Conference on Antimicrobial Agents and Che-motherapy New Orleans, USA (1996):F86.
   Google Scholar
• PATTERSON BE, COATES PE: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995):F78.
   Google Scholar
• JEQEQUEL SG, GIBSON A, HYLAND R et al.: UK-109,496, a novel, wide-spectrum triazole derivative for the treat-ment of fungal infections: disposition in man. 35th Interscience Conference on Antimicrobial Agents and Che-motherapy San Francisco, USA (1995):F79.
   Google Scholar
• DENNING DW, DEL FAVERO A, GLUCKMAN E et al: UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis. 35th Interscience Confer-ence on Antimicrobial Agents and Chemotherapy San Fran-cisco, USA (1995):F80.
   Google Scholar
• DUPONT B, DENNING D, LODE H et al: UK-109,496, a novel, wide-spectrum triazole derivative for the treat-ment of fungal infections: clinical efficacy in chronic invasive aspergillosis. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy.San Francisco, USA (1995):F81.
   Google Scholar
• NAITO T, KAKU Y, TSURUOKA A eta].: ER-30346, a novel antifungal triazole: 1. Synthesis and structure-activity relationships of new thiazole-containing triazole anti-fungals. 35th Interscience Conference on Antimicrobial Agents and ChemotherapySan Francisco, USA (1995):F91.
   Google Scholar
• HATA K, KIMURA J, MIKI H et al: In vitro and in vivo antifungal activities of ER30346, a novel oral triazolewith a broad antifungal spectrum. Antimicrob. Agents Chemother. (1996) 40:2237–2242.
   Google Scholar
• A compr ehensive comparison of ER-30346, fluconazole and itracona-zole activities.
   Google Scholar
• HATA K, UENO J, MIKI H et al.: ER-30346, a novel antifungal triazole: Ill. In vitro activity and its mode of action. 35th Interscience Conference on Antimicrobial Agents and ChemotherapySan Francisco, USA (1995):F92.
   Google Scholar
• NAKAMURA T, SAKAI R, SONODA J et al.: ER-30346, a novel antifungal triazole: IV. Pharmacokinetic and toxi-cological studies in mice, rats and dogs. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, USA (1995):F94.
   Google Scholar
• TOYOSAWA T, HATAK, UENO J eta].: ER-30346, a novel antifungal triazole: II. In vivo activity against experi-mental infections. 35th Interscience Conference on Antimi-crobial Agents and Chemotherapy. San Francisco, USA (1995)93.
   Google Scholar
• HATA K, KIMURA J, MIKI H eta].: Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococ-cosis. Antimicrob. Agnts Chemother. (1996) 40:2243–2247.
   Google Scholar
• BOYLE T, FILMAN DT, GRAVESTOCK MB, WARDLEWORTH JM: Synthesis and structure-activity relationship of a novel antifungal agent ICI 195,739. Ann. N. Y Acad. Sci. (1988) 544:86–100.
   PubMedGoogle Scholar
• RYLEY JF, MCGREGOR S, WILSON RG: Activity of ICI 195,739 - a novel, orally active bistriazole - in rodent models of fungal and protozoal infections. Ann. N. Y Acad. Sci. (1988) 544:310–328.
   PubMedGoogle Scholar
• YAMADA H. TOSHIHIKO T, WATANABE T et al.: In vitro and in vivoantifungal activities of D0870, a new triazole agent. Antimicrob. Agents Chemother. (1993) 37:2414–2417.
   Google Scholar
• VENKATESWARLU K, DENNING DW, MANNING NJ, KELLY SL: Comparison of D0870, a new triazole antifungal agent, to fluconazole for inhibition of Candida albicans cytochrome P-450 by using in vitro assays. Antimicrob. Agents Chemother. (1996) 40:1382–1286.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, BALE MJ, BUSCHELMAN B, RHOMBERG P:
   Google Scholar
• •Antifungal activity of a new triazole, D0870, compared with four other antifungal agents tested against clinical isolates of Candida and Torulopsis glabrata. Diagn. MicrobioL Infect. Dis. (1994) 19:75–80.
   PubMed Web of Science ®Google Scholar
• A comprehensive comparison of D0870, itraconazole and flucona-zole MIC values against yeasts.
   Google Scholar
• PENG T, GALGIANI JN: In vitro studies of a new antifun-gal triazole, D0870, against Candida albicans, Crypto-coccus neoformans, and other pathogenic yeasts. Antimicrob. Agnts Chemother. (1993) 37:2126–2131.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, COFFMANN S: Comparison of visual and spectrophotometric methods of MIC end-point determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870.j Clin. Microbiol. (1995) 33:1094–1097.
   PubMed Web of Science ®Google Scholar
• WARDLE HM, LAW D., MOORE CB eta].: In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida spp. Antimicrob. Agents Chemother. (1995) 39:868–871.
   Google Scholar
• BARCHIESI F, HOLLIS RJ, DEL POETA M et al.: Transmis-sion of fluconazole-resistant Candida albicans betwee patients with AIDS and oropharyngeal candidiasis by pulsed-field gel electrophoresis. Clin. Infect. Dis. (1995) 21:S61–S64.
   Google Scholar
• BARCHIESI F, COLOMBO AL, MCGOUGH DA et al: In vitro activity of a new triazole, D0870, against Candida albi-cans isolates from oral cavities of patients infected with human immunodeficiency virus. Antimicrob. Agnts Chemother. (1994) 38:2553–2556.
   PubMed Web of Science ®Google Scholar
• MOCHIZUKI H, YAMADA H, WATANABE T etaL: Excellent therapeutic efficacy of D0870, a triazole antifungal agent, against local infections and its mechanism of action. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (1993):377.
   Google Scholar
• MOCHIZUKI H, YAMADA H, WATANABE T eta].: Fungici-dal mechanism of D0870 against Crypt ococcus neofor-mans under acidic conditions. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco, USA (1995):F95.
   Google Scholar
• MOORE CB, LAW D, DENNING DW: In vitro activity of the new triazole D0870 compared with amp hote ricin B and itraconazole against Aspergillus spp. J. Antimicrob. Chemother. (1993) 32:831–836.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, HANSON LH, STEVENS DA: Activities of the triazole D0870 in vitro and against murine blastomy-cosis. Antimicrob. Agents Chemother. (1993) 37:1177–1179.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, STEVENS DA: Efficacy of the triazole D0870 in a murine model of systemic histoplasmosis. Antimi-crob. Agents Chemother. (1995) 39:778–780.
   PubMed Web of Science ®Google Scholar
• CLEMONS KV, STEVENS DA: Utility of the triazole D0870 in the treatment of experimental systemic coccidioi-domycosis. J. Med. Vet. Mycol. (1994) 32:323–326.
   PubMedGoogle Scholar
• HUMPHREY MJ, JEVONS S, TRABIT MEI: Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob. Agents Chemother. (1985) 28:648–653.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, NAJVAR LK, HOLMBERG JD, LUTHER MF: Fluconazole, D0870, and flucytosine treatment of dis-seminated Candida tropicalis infections in mice. An-timicrob. Ants Chemother. (1995) 39:924–929.
   PubMed Web of Science ®Google Scholar
• EDWARDS JR, NAIRN K, MEGSON GM, SHEPHERD GL, HUGHES GD: Activity of D0870 against Candida albicans and Cryptococcus neoformans showing reduced sus-ceptibility to fluconazole. 33rd Intel-science Conference on Antimicrobial Agents and Chemotherapy New Orleans, USA (1993)375.
   Google Scholar
• KARYOTAKIS N, ANAISSIE EJ, HACHEM R et al.: Compari-son of the efficacy of polyenes and triazoles against hematogenous Candida krusei infections in neu-tropenic mice. Infect. Dis. (1993) 168:1311–1313.
   Google Scholar
• KARYOTAKIS NC, DIGNANI MC, HACHEM R, ANAISSIE EJ: Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections. Antimicrob. Agents Chemother. (1995) 39:571–573.
   PubMed Web of Science ®Google Scholar
• CORREA AL, VELEZ G, ALBERT M et al.: Comparison of D0870 and fluconazole in the Ireatment of murine cryptococcal meningitis. J. Med. Vet Mycol. (1995) 33:367–374.
   PubMedGoogle Scholar
• DENNING DW, HALL L, JACKSON M, HOLLIS S: Efficacy of D0870 compared with those of itraconazole and am-photericin B in two murine models of invasive asper-gillosis. Andrnicrob. Agents Chemother. (1995) 39:1809–1814.
   PubMed Web of Science ®Google Scholar
• DE WIT S, O'DOHERTY E, SMITH RP et al.: Pharmacoki-netics of two multiple dosing regimens of D0870 in HIV positive patients: a Phase I study. 35th Intel-science Con-ference on Antimicrobial Agents and Chemotherapy San Francisco, USA (1995):F97.
   Google Scholar
• DE WITS, DUPONT B, CARTLEDGE JD et al: Pilot study of a new triazole derivative (D0870) in HIV patients with oral candidiasis. 34th Intel-science Conference on Antimi-crobial Agents and Chemotherapy. New Orleans, USA (1994): 1225.
   Google Scholar
• CARTLEDGE JD, DENNING D, DUPONT B etaL: Treatment of fluconazole resistant oral candidosis with D0870 in patients with AIDS. 34th Intel-science Conference on An-timicrobial Agents and Chemotherapy New Orleans, USA (1994):M89.
   Google Scholar